Definium Therapeutics, Inc. SEC filings DFTX

Definium Therapeutics, Inc. has 504 filings in SEC EDGAR's recent list, going back to Jun 8, 2020. Its latest annual report, Form 10-K, was filed on Feb 26, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 6, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 14, 2026 (regulation fd disclosure, other events). The company's fiscal year ends on December 31.

Definium Therapeutics, Inc. SEC filings
Form Description Filed Period
10-K Annual report Feb 26, 2026 Dec 31, 2025
ARS Annual report to shareholders Apr 23, 2025 Dec 31, 2024
10-K Annual report Mar 6, 2025 Dec 31, 2024
ARS Annual report to shareholders Apr 26, 2024 Dec 31, 2023
10-K Annual report Feb 28, 2024 Dec 31, 2023
ARS Annual report to shareholders May 1, 2023 Dec 31, 2022
10-K Annual report Mar 9, 2023 Dec 31, 2022
10-K Annual report Mar 28, 2022 Dec 31, 2021

Showing 8 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Medicinal Chemicals & Botanical Products (SIC 2833)
Listed as
DFTX (Nasdaq)
Fiscal year ends
December 31
Incorporated in
British Columbia, Canada
Headquarters
New York, NY
SEC filer status
, Emerging growth company
SEC CIK
1813814
Former names
Mind Medicine (MindMed) Inc. (until Jan 12, 2026)

Other Medicinal Chemicals & Botanical Products companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.